Save

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

PHASE1PHASE2RECRUITING

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Simpliy with AI

Study details:

This study is a Phase I/IIa modular, open-label, multi-center study of AZD5305 administered orally, either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

Age ≥ 18 at the time of screening

Histological or cytological confirmation of advanced malignancy considered to be suitable for study treatment and meeting module specific eligibility criteria.

Eastern Cooperative Oncology Group Performance status (ECOG PS: 0-2)

Life expectancy ≥ 12 weeks

Progressive cancer at the time of study entry

Patients must have evaluable disease as defined in module-specific criteria for Part A and Part B

Adequate organ and marrow function as defined by the protocol.

For Part B expansion cohorts: Provision of formalin-fixed and paraffin embedded (FFPE) tumour specimen is mandatory, where available, except if stated that it is optional in a specific Module.

Patients may have received up to one prior line of therapy with a PARPi-based regimen (either as a treatment or as maintenance)

Patients must not have received prior therapy with a PARPi-based regimen (either as a treatment or as maintenance)

Exclusion criteria

Treatment with any of the following:

1. Nitrosourea or mitomycin C within 6 weeks of the first dose of study treatment

2. Any investigational agents or study drugs from a previous clinical study within 5 half-lives or 3 weeks (whichever is shorter) of the first dose of study treatment

3. Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks of the first dose of study treatment

4. Any live virus or bacterial vaccine within 28 days of the first dose of study treatment

Concomitant use of medications or herbal supplements known to be cytochrome P450 3A4 (CYP3A4) strong and moderate inhibitors or inducers.

Concomitant use of drugs that are known to prolong or shorten QT and have a known risk of Torsades de Pointes.

Receiving continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for any reason.

Major surgery within 4 weeks of the first dose of study treatment.

Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study treatment.

Any history of persisting (> 2 weeks) severe pancytopenia due to any cause

Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of >10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.

Patient with known predisposition to bleeding (e.g., active peptic ulceration, recent [within 6 months] haemorrhagic stroke, proliferative diabetic retinopathy).

Cardiac conditions as defined by the clinical study protocol

Other cardiovascular diseases as defined by any of the following:

1. Symptomatic heart failure,

2. Uncontrolled hypertension,

3. Hypertensive heart disease with significant left ventricular hypertrophy

4. Acute coronary syndrome (ACS)/acute myocardial infarction (AMI), unstable angina pectoris, coronary intervention procedure with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 6 months.

5. Cardiomyopathy of any etiology

6. Presence of clinically significant valvular heart disease

7. History of atrial or ventricular arrhythmia requiring treatment; subjects with atrial fibrillation and optimally controlled ventricular rate (< 100 beats per minute) are permitted.

8. Subjects with atrial fibrillation and optimally controlled ventricular rate are permitted

9. Transient ischaemic attack, or stroke within 6 months prior to screening

10. Patients with symptomatic hypotension at screening

Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).

Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD5305

Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).

Prior malignancy whose natural history, in the Investigator's opinion, has the potential to interfere with safety and efficacy assessments of the investigational regimen.

Other module-specific criteria may apply

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : No

Gender eligible for study: All

Things to know

Study dates

Study start: 2020-11-12

Primary completion: 2027-03-03

Study completion finish: 2027-03-03

Study type

TREATMENT

Phase

PHASE1

PHASE2

Trial ID

NCT04644068

Intervention or treatment

DRUG: AZD5305

DRUG: Paclitaxel

DRUG: Carboplatin

DRUG: T- Dxd

DRUG: Dato-DXd

DRUG: Camizestrant

Conditions

• Ovarian Cancer
• Breast Cancer
• Pancreatic Cancer
• Prostate Cancer
• Non-small Cell Lung Cancer
• Colorectal Cancer
• Bladder Cancer
• Gastric Cancer
• Cervical Cancer
• Endometrial Cancer
• Additional Indications Below for Module 4 and 5
• Biliary Cancer
• Small Cell Lung Cancer Only in Module 5

Condition: Ovarian Cancer, Breast Cancer and more
DRUG: AZD5305 and other drugs
Melbourne, Not Specified, Australia
Sponsor: AstraZeneca

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Research Site

Research sites nearby

Select from list below to view details:

Research Site
Melbourne, Not Specified, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: Module 1: AZD5305 Monotherapy AZD5305 Monotherapy	DRUG: AZD5305 Oral PARP inhibitor
EXPERIMENTAL: Module 2: AZD5305 + Paclitaxel AZD5305 + Paclitaxel	DRUG: AZD5305 Oral PARP inhibitor
EXPERIMENTAL: Module 3: AZD5305 + Carboplatin with or without Paclitaxel AZD5305 + Carboplatin with or without Paclitaxel	DRUG: AZD5305 Oral PARP inhibitor
EXPERIMENTAL: Module 4: AZD5305 + Trastuzumab Deruxtecan AZD5305 + T- DXd	DRUG: AZD5305 Oral PARP inhibitor
EXPERIMENTAL: Module 5 AZD5305 + Datopotamab Deruxtecan AZD5305 + Dato-DXd	DRUG: AZD5305 Oral PARP inhibitor
EXPERIMENTAL: Module 6 AZD5305 + Camizestrant AZD5305 + Camizestrant	DRUG: AZD5305 Oral PARP inhibitor

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
The number of subjects with adverse events/serious adverse events	Number of patients with adverse events and with serious adverse events including abnormal clinical observations, abnormal ECG parameters, abnormal laboratory assessments and abnormal vital signs that changed from baseline	From time of Informed Consent to 28 + 7 days post last dose ( modules 1,2,3,5 and 6). 40+7 days post last dose for Module 4.
The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.	A DLT is defined as any toxicity that occurs from the first dose of study treatment (either AZD5305 or combination anti-cancer agent) up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation. DLTs occurring outside the DLT window (ie, late onset toxicities) may be defined as a DLT after consultation with the sponsor and investigators, based on the emerging safety profile.	From first dose of study treatment until the end of Cycle 1.

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Best percentage change in target lesion	Change in target lesion size from baseline, as defined by RECIST 1.1.	From Screening to confirmed progressive disease (approximately 1 year)
Objective Response Rate	Best response until progression, as defined by RECIST 1.1.	From Screening to confirmed progressive disease (approximately 1 year)
Duration of Response	Time from first response to progression or death , as defined by RECIST 1.1.	From Screening to confirmed progressive disease (approximately 1 year)
Progression Free Survival	Time from C1D1 to progression or death, as defined by RECIST 1.1.	From Screening to confirmed progressive disease (approximately 1 year)
Time To Response	Time from C1D1 to complete or partial response, as defined by RECIST 1.1.	From Screening to confirmed progressive disease (approximately 1 year)
Effects of AZD5305 on pH2AX (Ser139) PD biomarker	Measure change from baseline in pH2AX	From Cycle 0 Day 1 to Cycle 1 Day 15 (approximately 21 days)
CA125 response (ovarian cancer)	at least a 50% reduction in CA125 levels from a pre-treatment sample as defined by GCIG criteria.	From Screening to confirmed progressive disease (approximately 1 year)
Module 1: Area Under Curve (AUC)	The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 1: Maximum plasma concentration of the drug (Cmax)	The concentration of AZD5305 in plasma will be determined (Cmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 1: The time taken to reach the maximum concentration (Tmax)	The concentration of AZD5305 in plasma will be determined (Tmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 1 and Module 5: Objective Response Rate (prostate cancer)	Best response until progression, as defined by RECIST 1.1 or PCWG3 (bone)	From Screening to confirmed progressive disease (approximately 1 year)
Module 1: Radiographic progression free survival (prostate cancer)	Time from C1D1 to progression or death, as defined by RECIST 1.1 and PCWG3(bone).	From Screening to confirmed progressive disease (approximately 1 year)
Module 1: Proportion of subjects with ≥ 50% PSA decrease (prostate cancer)	PSA from baseline to the lowest post-baseline PSA result, confirmed by a second consecutive PSA assessment	From Screening to confirmed progressive disease (approximately 1 year)
Module 1 : To investigate the effect of a high-fat meal on the PK of AZD5305	Effect on High fat meal on PK parameters of AZD5305.PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without food	Cycle 0, Day 1 (C0D1), in either the "fasted" or "fed" state, followed by a single oral dose of AZD5305 in the other state for Cycle 1, Day 1 (C1D1) at least 72 hours later; 1 cycle is 28 days.
Module 2: Area Under Curve (AUC)	The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2: Maximum plasma concentration of the drug (Cmax)	The concentration of AZD5305 in plasma will be determined (Cmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 2: The time taken to reach the maximum concentration (Tmax)	The concentration of AZD5305 in plasma will be determined (Tmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 3: Area Under Curve (AUC)	The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 3: Maximum plasma concentration of the drug (Cmax)	The concentration of AZD5305 in plasma will be determined (Cmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 3: The time taken to reach the maximum concentration (Tmax)	The concentration of AZD5305 in plasma will be determined (Tmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4 : Area Under Curve	The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4: Maximum plasma concentration of the drug (Cmax)	The concentration of AZD5305 in plasma will be determined (Cmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4: The time taken to reach the maximum concentration (Tmax)	The concentration of AZD5305 in plasma will be determined (Tmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 4: Anti-Drug Antibody (ADA)	To investigate the presence of ADAs for T-DXd	Samples will be collected within 1 hour before dose administration on Day 1 of Cycle 1, 2, and 4, then every 4 Cycles (each cycle is 21 days), EoT, and at safety follow-up (40 days after last dose) as per Schedule of Assessments
Module 4: To assess the preliminary anti-tumour activity of AZD5305 as monotherapy and in combination with T-DXd.	Time from C1D1 to progression or death, as defined by RECIST v 1.1 summarised at the 6 month landmark (PFS6)	From screening to approximately 6 months
Module 5: Area Under Curve	The concentration of AZD5305 in plasma will be determined. Area under the curve is the integral of the concentration-time curve. The AUC reflects the actual body exposure to drug after administration. The AUC is dependent on the rate of elimination of the drug from the body and the dose administered.	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 5: Maximum plasma concentration of the drug (Cmax)	The concentration of AZD5305 in plasma will be determined (Cmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 5: The time taken to reach the maximum concentration (Tmax)	The concentration of AZD5305 in plasma will be determined (Tmax will be derived).	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 5: Anti-Drug Antibody (ADA)	Presence of ADAs for Dato-DXd	Whole blood samples for determination of ADA for Dato-DXd in plasma will be collected in patients receiving Dato-DXd per the schedule specified in the SoA : Day 1 of Cycle 1, 2, 4, and 8 (each cycle is 21 days) , EoT, and then 28 day follow up visit.
Module 5: Premilinary anti tumour activity AZD5305 in combination with	objective response rate and radiographic progression-free survival using RECIST v1.1. Proportion of patients achieving a ≥ 50% decrease in PSA from baseline to the post-baseline PSA result, confirmed by a second consecutive PSA assessment at least 3 weeks later (PSA50 response).	From screening to confirmed progresive disease ( approximately 12 weeks)
Module 6: To characterise the PK of AZD5305 and camizestrant following a single dose and at steady state after multiple dosing, when given in combination.	Plasma concentrations and PK parameters of AZD5305 and camizestrant after single dose and multiple dose administration, including, but not limited to: AUC, Cmax, Tmax, as data allow	At predefined interval throughout the treatment (approximately 12 weeks)
Module 6: To evaluate the effect of camizestrant on the PK of AZD5305.	PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without camizestrant.	At predefined intervals throughout the treatment period (approximately 12 weeks)
Module 6: To evaluate the effect of AZD5305 on the PK of Camizestrant.	PK parameters, including but not limited to AUC and/or AUC(0-t), Cmax, Tmax, AUC(0-t) and Cmax ratio, with and without AZD5305.	At predefined intervals throughout the treatment period (approximately 12 weeks)

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies